22:01:01 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriLäkemedel & Handel
Nordic Nanovector är ett läkemedelsbolag. Bolaget specialiserar sig inom utveckling av antikroppsläkemedel för behandling utav hematologisk cancer. Störst specialisering återfinns inom precisionsterapi som används i den kliniska fasen. Övriga sjukdomar som behandlas är non-hodgkins lymfom (NHL). Bolaget grundades under 2009 och har sitt huvudkontor i Oslo.

Kalender

2022-11-10 Kvartalsrapport 2022-Q3
2022-08-31 Kvartalsrapport 2022-Q2
2022-05-13 Kvartalsrapport 2022-Q1
2022-04-29 Ordinarie utdelning NANOV 0.00 NOK
2022-04-28 Årsstämma 2022
2022-03-01 Bokslutskommuniké 2021
2022-02-14 Extra Bolagsstämma 2022
2021-11-18 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-26 Kvartalsrapport 2021-Q1
2021-04-28 Årsstämma 2021
2021-04-16 Ordinarie utdelning NANOV 0.00 NOK
2021-03-22 Extra Bolagsstämma 2021
2021-02-18 Bokslutskommuniké 2020
2020-11-19 Kvartalsrapport 2020-Q3
2020-10-21 Extra Bolagsstämma 2020
2020-08-27 Kvartalsrapport 2020-Q2
2020-06-11 Ordinarie utdelning NANOV 0.00 NOK
2020-06-10 Årsstämma 2020
2020-05-26 Kvartalsrapport 2020-Q1
2020-02-27 Bokslutskommuniké 2019
2019-11-19 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-23 Kvartalsrapport 2019-Q1
2019-04-26 Ordinarie utdelning NANOV 0.00 NOK
2019-04-25 Årsstämma 2019
2019-02-18 Extra Bolagsstämma 2019
2018-08-22 Kvartalsrapport 2018-Q2
2018-05-31 Ordinarie utdelning NANOV 0.00 NOK
2018-05-30 Kvartalsrapport 2018-Q1
2018-05-30 Årsstämma 2018
2018-02-27 Bokslutskommuniké 2017
2017-12-20 Extra Bolagsstämma 2017
2017-11-22 Kvartalsrapport 2017-Q3
2017-08-23 Kvartalsrapport 2017-Q2
2017-05-26 Ordinarie utdelning NANOV 0.00 NOK
2017-05-24 Kvartalsrapport 2017-Q1
2017-05-24 Årsstämma 2017
2017-02-28 Bokslutskommuniké 2016
2016-11-23 Kvartalsrapport 2016-Q3
2016-10-12 Extra Bolagsstämma 2016
2016-08-24 Kvartalsrapport 2016-Q2
2016-05-31 Kapitalmarknadsdag 2016
2016-05-20 Ordinarie utdelning NANOV 0.00 NOK
2016-05-19 Kvartalsrapport 2016-Q1
2016-05-19 Årsstämma 2016
2016-02-26 Bokslutskommuniké 2015
2015-11-17 Kapitalmarknadsdag 2015
2015-10-21 Kvartalsrapport 2015-Q3
2015-08-26 Kvartalsrapport 2015-Q2
2015-05-27 Kvartalsrapport 2015-Q1
2015-03-09 Årsstämma 2015
2014-11-12 Extra Bolagsstämma 2014
2021-03-01 15:38:19
Not for release, publication or distribution, directly or indirectly, in the
United States of America, Canada, Japan or Australia

THIS IS A RESTRICTED COMMUNICATION AND YOU MUST NOT FORWARD IT OR ITS CONTENTS
TO ANY PERSON TO WHOM FORWARDING THIS COMMUNICATION IS PROHIBITED BY THE LEGENDS
CONTAINED HEREIN

Oslo, Norway, 1 March 2021

Reference is made to the stock exchange announcements by Nordic Nanovector ASA
("Nordic Nanovector" or the "Company") on 23 February 2021 regarding the
successfully completed private placement of 15,878,122 new shares (the "Private
Placement Shares") in the Company (the "Private Placement"), and a potential
subsequent repair offering of up to 2,699,280 new shares (the "Offer Shares") in
the Company (the "Repair Offering").

The share capital increase pertaining to the Private Placement was resolved by
the board of directors of the Company (the "Board") on 23 February 2021 pursuant
to an authorisation by the Company's general meeting held 21 October 2020, while
the completion of the Repair Offering is subject to the approval by the
extraordinary general meeting.

Nordic Nanovector hereby calls for an extraordinary general meeting in the
Company to be held on 22 March 2021 at 11.00 CET at the Company's offices at
Kjelsåsveien 168, 0884 Oslo, Norway.

The following matters are on the agenda: an authorisation to the Board to issue
the new shares in the Repair Offering.

The Repair Offering is, inter alia, conditional upon (i) the board of directors
resolving to initiate the Repair Offering as described in the stock exchange
announcement by the Company on 23 February 2021 (ii) the general meeting making
the necessary resolution to grant the board with an authorisation to increase
the share capital in connection with the Repair Offering, and (iii) the
publication of a prospectus approved by the Norwegian Financial Supervisory
Authority.

The formal resolution (including the final number of new shares to be offered)
related to the Repair Offering will be made by the board of directors following
the EGM and the approval and subsequent publication of a prospectus prepared in
connection with the Repair Offering. The board of directors may, in its sole
discretion, decide that the Company shall not carry out the Repair Offering,
inter alia if the prevailing market price of the Company's shares trade lower
than the subscription price and thereby making a repair offering redundant.

The Repair Offering will, if implemented, be directed towards eligible
shareholders in the Company who (i) are shareholders as of 23 February 2021, as
registered in the VPS as of 25 February 2021, (ii) are not allocated Offer
Shares in the Private Placement and (iii) are not resident in a jurisdiction
where such offering would be unlawful or, would (in jurisdictions other than
Norway) require any prospectus, filing, registration or similar action (the
"Eligible Shareholders"). The Eligible Shareholders will be granted non-tradable
subscription rights. Over-subscription will be permitted, but subscription
without subscription rights will not be permitted in the Repair Offering. The
subscription period in the Repair Offering is expected to commence on or about
25 March 2021, and the subscription price in the Repair Offering will be the
same as in the Private Placement.

Due to the restrictions caused by COVID-19 and the advice from the Norwegian
government in connection therewith, all shareholders are encouraged to exercise
their shareholder rights without physical attendance at the general meeting,
either through advance electronically voting through VPS Investor Services or by
using the enclosed proxy form to provide proxy to the Chairman Jan Hendrik
Egberts (or the person he appoints).

Shareholders may dial-in and listen to the general meeting. Call-in details will
be made available on the Company's website in due time in advance of the general
meeting. Please note that shareholders will not be able to exercise their
shareholder rights, including casting votes or to ask questions, through the
telephone conference.

The full notice with appendices are attached. The notice and the documents to
which it refers are also available on www.nordicnanovector.com.

Shareholders wishing to attend the Extraordinary General Meeting, in person or
by proxy, must complete and return the attendance form or power of attorney form
attached to the notice to Nordea Bank Abp, Issuer Service, Postboks 1166
Sentrum, N-0107 Oslo, or by email to nis@nordea.com no later than 19 March 2021,
16:00 CET.

ABG Sundal Collier ASA, Carnegie AS and DNB Markets, a part of DNB Bank ASA
acted as Joint Global Coordinators and Joint Bookrunners in connection with the
Private Placement (the "Managers") and the Repair Offering. Advokatfirmaet
Selmer AS is acting as legal advisor to Nordic Nanovector.

For further information, please contact:

IR enquiries

Malene Brondberg, CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com

Media Enquiries

Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)
Tel: +44 203 926 8535
Email: nordicnanovector@citigatedewerogerson.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector's lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with
substantial unmet medical need, representing a growing market forecast to be
worth nearly USD 29 billion by 2026. Nordic Nanovector retains global marketing
rights to Betalutin® and intends to actively participate in the
commercialisation of Betalutin® in the US and other major markets.

Further information can be found at www.nordicnanovector.com.

This information is subject to a duty of disclosure pursuant to Section 5-12 of
the Securities Trading Act.

Important Notices

This document is not an offer to sell or a solicitation of offers to purchase or
subscribe for shares. Copies of this document may not be sent to jurisdictions,
or distributed in or sent from jurisdictions, in which this is barred or
prohibited by law. The information contained herein shall not constitute an
offer to sell or the solicitation of an offer to buy, in any jurisdiction in
which such offer or solicitation would be unlawful absent registration, or an
exemption from registration or qualification under the securities laws of any
jurisdiction.

This document is not for publication or distribution in the United States of
America, Canada, Australia or Japan and it does not constitute an offer or
invitation to subscribe for or purchase any securities in such countries or in
any other jurisdiction. In particular, the document and the information
contained herein should not be distributed or otherwise transmitted into the
United States of America or to U.S. persons (as defined in the U.S. Securities
Act of 1933, as amended (the "Securities Act") or to publications with a general
circulation in the United States of America. This document is not an offer for
sale of securities in the United States of America. The securities referred to
herein have not been and will not be registered under the Securities Act, or the
laws of any state, and may not be offered or sold in the United States of
America absent registration under or an exemption from registration under the
Securities Act. Nordic Nanovector does not intend to register any part of the
Private Placement in the United States of America.

There has not been made and will not be made any public offering of the
securities in the United States of America. Any public offering in the United
States of America would be made by means of a prospectus containing detailed
information about the company and management, as well as financial statements.

The information contained herein does not constitute an offer of securities to
the public in the United Kingdom. No prospectus offering securities to the
public will be published in the United Kingdom. This document is only being
distributed to and is only directed at (i) persons who are outside the United
Kingdom or (ii) to investment professionals falling within article 19(5) of the
Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the
"Order") or (iii) high net worth entities, and other persons to whom it may
lawfully be communicated, falling within article 49(2)(a) to (d) of the Order
(all such persons together being referred to as "relevant persons"). The
securities are only available to, and any invitation, offer or agreement to
subscribe, purchase or otherwise acquire such securities will be engaged in only
with, relevant persons.

Any person who is not a relevant person should not act or rely on this document
or any of its contents. Any offer of securities to the public that may be deemed
to be made pursuant to this communication in any member state of the European
Economic Area (each an "EEA Member State") that has implemented Regulation
2017/1129 (the "Prospectus Regulation") is only addressed to qualified investors
in that Member State within the meaning of the Prospectus Regulation.

The information contained in this document does not purport to be comprehensive.
None of the Managers, any of their respective subsidiary undertakings or
affiliates, or their respective directors, officers, employees, advisers or
agents accepts any responsibility or liability whatsoever for (whether in
contract, tort or otherwise) or makes any representation or warranty, express or
implied, as to the truth, accuracy or completeness of the information in this
document (or whether any information has been omitted from the document) or any
other information relating to the Company, its subsidiaries, affiliates or
associated companies, whether written, oral or in a visual or electronic form,
and howsoever transmitted or made available or for any loss howsoever arising
from any use of this document or its contents or otherwise arising in connection
therewith. The Managers disclaim any responsibility for any acts or omissions of
the Company, any of the Directors or any other person in connection with the
Private Placement.

The Managers are acting for the Company in connection with the Private Placement
and no one else and will not be responsible to anyone other than the Company for
providing the protections afforded to their respective clients or for providing
advice in relation to the Private Placement or any transaction or arrangement
referred to in this press release.

Solely for the purposes of the product governance requirements contained within:
(a) EU Directive 2014/65/EU on markets in financial instruments, as amended
("MiFID II")